Get the Stockscreener App
6.27
2.03%
-0.13
Eupraxia Pharmaceuticals Inc stock is traded at $6.27, with a volume of 87,787.
It is down -2.03% in the last 24 hours and down -5.00% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$6.40
Open:
$6.58
24h Volume:
87,787
Relative Volume:
0.73
Market Cap:
$317.57M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-8.1429
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
-0.16%
1M Performance:
-5.00%
6M Performance:
+61.39%
1Y Performance:
+85.78%
1-Day Range:
$6.115
$6.58
1-Week Range:
$5.95
$6.8499
52-Week Range:
$2.6801
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.27 | 324.15M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX.WT.A) Risk-Controlled Trading Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.3% – Here’s Why - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Strong-Buy at Lifesci Capital - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen - Defense World
New Highs: How Eupraxia Pharmaceuticals Inc stock reacts to global recession fears2025 Historical Comparison & Fast Moving Trade Plans - moha.gov.vn
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to "Strong-Buy" at Lifesci Capital - MarketBeat
Eupraxia Pharmaceuticals Inc. (EPRXF) Competitors - Meyka
(EPRX.WT.A) Investment Analysis and Advice - news.stocktradersdaily.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Analysts see more than 77% upside for Eupraxia Pharmaceuticals (EPRX), here’s why - MSN
CapEx per share of Eupraxia Pharmaceuticals Inc Warrant 2021-09.03.2026 on Eupraxia Pharma Rg – TSX:EPRX.WT - TradingView
Is Eupraxia Pharmaceuticals Inc. stock oversold or undervaluedWeekly Trade Review & Verified Technical Signals - Newser
Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why - Finviz
Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Net current asset value per share of Eupraxia Pharmaceuticals, Inc. – LS:A3EGRS - TradingView
Is Eupraxia Pharmaceuticals Inc. stock a bargain at current levelsWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Is Eupraxia Pharmaceuticals Inc. (X43) stock testing key supportJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
How Eupraxia Pharmaceuticals Inc. (X43) stock correlates with oil markets2025 Institutional Moves & Weekly High Potential Alerts - Newser
How forex fluctuations impact Eupraxia Pharmaceuticals Inc. (X43) stockPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Eupraxia Pharmaceuticals Inc. (X43) stock expanding market penetration2025 Key Lessons & Low Risk High Win Rate Picks - Newser
(EPRX) Investment Analysis and Advice (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. (EPRX.TO) stock price, news, quote and history - Yahoo Finance UK
Eupraxia Pharmaceuticals (EPRX) Stock Analysis Report | Financials & Insights - Benzinga
How Eupraxia Pharmaceuticals Inc. (X43) stock behaves under inflation pressureOptions Play & Daily Profit Focused Stock Screening - Newser
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
Scotia Capital Inc. Reduces Stake in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
(EPRX.WT.A) On The My Stocks Page - news.stocktradersdaily.com
Will Eupraxia Pharmaceuticals Inc. stock deliver better than expected guidanceChart Signals & Expert Approved Momentum Trade Ideas - moha.gov.vn
Paul Brennan Bought 60% More Shares In Eupraxia Pharmaceuticals - simplywall.st
Eupraxia Pharmaceuticals Appoints New CFO Amid Leadership Transition - MSN
Why Eupraxia Pharmaceuticals Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Based Buy/Sell Signal Reports - moha.gov.vn
Eupraxia Pharmaceuticals Inc. $EPRX Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Will Eupraxia Pharmaceuticals Inc. stock reach Wall Street targetsMarket Sentiment Summary & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
(EPRX) Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Long Term Investment Analysis - news.stocktradersdaily.com
Wall Street Zen Downgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to Sell - MarketBeat
(EPRX) Investment Report (EPRX:CA) - news.stocktradersdaily.com
Why Eupraxia Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Bank of Montreal Can Has $215,000 Holdings in Eupraxia Pharmaceuticals Inc. $EPRX - Defense World
Is Eupraxia Pharmaceuticals Inc. (X43) stock supported by strong fundamentals2025 Market Overview & Real-Time Volume Analysis - newser.com
Eupraxia Pharmaceuticals Inc. stock trend forecastTrade Ideas & Fast Moving Market Watchlists - newser.com
How Eupraxia Pharmaceuticals Inc. (X43) stock compares with top peersMarket Rally & Risk Managed Investment Strategies - newser.com
Is Eupraxia Pharmaceuticals Inc. (X43) stock good for long term investingJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):